Estonia

This is the reason Estonia matters. An Estonian digiretsept can be dispensed by pharmacies in Croatia, Cyprus, Czechia, Finland, Greece, Latvia, Lithuania, Poland, Portugal and Spain, through the EU cross-border ePrescription and eDispensing infrastructure. The patient identifies themselves at a foreign pharmacy, the pharmacy queries the Estonian prescription centre, and the medicine is dispensed locally.

Read carefully, that is a prescription-recognition network, not a dispensing network. It does not create a right to ship medicines across borders, and it does not override a destination country’s dispensing rules. What it does is make an Estonian-issued prescription usable in a set of markets where a locally issued one would otherwise be required.

For an operator, the question is whether an Estonian prescriber can lawfully issue to a patient who is resident abroad and never travels. Cross-border eDispensing was built for the travelling patient; using it as a routine domestic channel in another member state is the same untested manoeuvre visible in the Hungarian Hi-Doctor model, just with better plumbing.

Estonia liberalised pharmacy ownership, then reversed. The current regime under the Ravimiseadus requires that a pharmacy be majority-owned by a pharmacist, with a transition period that ran to 2020 and forced chains to restructure or divest.

What makes Estonia unusually strict is the case law. In 2021 the Riigikohus, the Supreme Court, addressed structures in which formal pharmacist ownership sat on top of continuing wholesaler or chain control through supply agreements, financing and management contracts. The rulings direct the regulator to assess actual control rather than the formal shareholding, which is exactly the test that nominee arrangements are designed to fail.

The practical conclusion for a founder is blunt: the standard workaround of a pharmacist figurehead with commercial control retained elsewhere is not merely risky in Estonia, it is the specific fact pattern the highest court has already ruled on.

With 1.4 million people and no obesity reimbursement, the Estonian demand market cannot support a dedicated operator. Every reason to be present here is structural: a mature national digital identity system, a universal e-prescription system with the widest cross-border recognition in the EU, English-capable technical talent, and a cheap, fast company formation regime including e-Residency.

That makes Estonia a plausible base for the software, identity and clinical-record layer of a European operation, while the licensed pharmacy assets sit in a jurisdiction with open ownership such as Czechia, Poland or Portugal, and the mail-order dispensing sits in the Netherlands.

Tervisekassa, the health insurance fund, reimburses semaglutide for type 2 diabetes under standard indication conditions. Obesity is not a reimbursed indication, so Wegovy, Saxenda and Mounjaro for weight management are self-pay at euro prices comparable with the wider Baltic and Nordic region.

Because the market is small, price transparency is limited and pharmacy-level variation is wide.